Open AccessTargeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial
Author(s) -
Sumanta K. Pal,
Diederik M. Somford,
Petros Grivas,
Srikala S. Sridhar,
Shilpa Gupta,
Joaquim Bellmunt,
Guru Sonpavde,
Mark T. Fleming,
Seth P. Lerner,
Yohann Loriot,
Jean H. Hoffman-Censits,
Begoña P. Valderrama,
Corina Andresen,
Marco J. Schnabel,
Suzanne Cole,
Siamak Daneshmand
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-1629
Subject(s) - medicine , metastatic urothelial carcinoma , clinical endpoint , placebo , tolerability , oncology , adjuvant , bladder cancer , cisplatin , urology , randomized controlled trial , cancer , urothelial carcinoma , adverse effect , chemotherapy , pathology , alternative medicine